Innate Pharma annual current ratio
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma Current Ratio Growth & History (IPH)
Innate Pharma's current ratio was 1.27 for fiscal 2025.
View full Innate Pharma company overviewInnate Pharma annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.27 | −1.33 | −50.97% |
| 2024 | 2024-12-31 | 2.60 | −1.13 | −30.38% |
| 2023 | 2023-12-31 | 3.73 | 0.35 | +10.40% |
| 2022 | 2022-12-31 | 3.38 | 1.65 | +95.45% |
| 2021 | 2021-12-31 | 1.73 | −2.08 | −54.61% |
| 2020 | 2020-12-31 | 3.81 | 1.86 | +95.50% |
| 2019 | 2019-12-31 | 1.95 | 0.33 | +20.05% |
| 2018 | 2018-12-31 | 1.62 | −0.24 | −12.68% |
| 2017 | 2017-12-31 | 1.86 | — | — |
Innate Pharma quarterly current ratio
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 1.27 | −1.33 | −50.97% |
| Q2 2025 | 2025-06-30 | 2.21 | −0.71 | −24.36% |
| Q4 2024 | 2024-12-31 | 2.60 | −1.13 | −30.38% |
| Q2 2024 | 2024-06-30 | 2.92 | −0.92 | −23.87% |
| Q4 2023 | 2023-12-31 | 3.73 | 0.35 | +10.40% |
| Q2 2023 | 2023-06-30 | 3.84 | 1.50 | +64.21% |
| Q4 2022 | 2022-12-31 | 3.38 | 1.65 | +95.45% |
| Q2 2022 | 2022-06-30 | 2.34 | −0.71 | −23.25% |
| Q4 2021 | 2021-12-31 | 1.73 | −2.08 | −54.61% |
| Q2 2021 | 2021-06-30 | 3.04 | — | — |
| Q4 2020 | 2020-12-31 | 3.81 | — | — |
Innate Pharma current ratio trends
Over the last five fiscal years, Innate Pharma's current ratio decreased from 3.81 to 1.27, a change of −2.54. The latest reported quarter, Q4 2025, shows 1.27.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Innate Pharma source filings ↗